Expertise in
15
conditions

Dr. Chaitali Nangia

Hematology | Oncology
Office
16105 Sand Canyon Ave Ste 230, 
Irvine, CA 
Offers Telehealth
Expertise in
15
conditions
Office
16105 Sand Canyon Ave Ste 230, 
Irvine, CA 

Overview

Chaitali Nangia is a Hematologist and an Oncologist in Irvine, California. Dr. Nangia is highly rated in 15 conditions, according to our data. Her top areas of expertise are Breast Cancer, Olfactory Neuroblastoma, Teratocarcinosarcoma, and Paget Disease of the Breast.

Her clinical research consists of co-authoring 18 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Hoag Memorial Hospital Presbyterian

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Office
16105 Sand Canyon Ave Ste 230, Irvine, CA 92618
Other Locations
Valentina Dalili-Shoaie M.D. Inc.
1 Hoag Dr Bldg 41, Newport Beach, CA 92663

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Drug, Biological
Study Drugs: SV-BR-1-GM, INCMGA00012, Low Dose Cyclophosphamide, Interferon Inoculation, Epacadosta
Study Phase: Phase 1/Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Biological, Drug, Procedure
Study Drugs: N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Irinotecan liposome
Study Phase: Phase 2
Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 11, 2025
Intervention Type: Other, Biological
Study Phase: Phase 1
Phase 1/2 Study of the Safety, Reactogenicity, and Immunogenicity of a Supplemental Spike & Nucleocapsid-targeted COVID-19 Vaccine to Enhance T Cell Based Immunogenicity in Participants Who Have Already Received Prime + Boost Vaccines Authorized For Emergency Use
Phase 1/2 Study of the Safety, Reactogenicity, and Immunogenicity of a Supplemental Spike & Nucleocapsid-targeted COVID-19 Vaccine to Enhance T Cell Based Immunogenicity in Participants Who Have Already Received Prime + Boost Vaccines Authorized For Emergency Use
Enrollment Status: Withdrawn
Publish Date: February 21, 2025
Intervention Type: Biological
Study Drug: hAd5-S-Fusion+N-ETSD COVID-19 Vaccine
Study Phase: Phase 1/Phase 2
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects With Advanced Triple-Negative Breast Cancer After Prior Therapy
Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects With Advanced Triple-Negative Breast Cancer After Prior Therapy
Enrollment Status: Terminated
Publish Date: June 12, 2024
Intervention Type: Biological, Drug
Study Drugs: N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

18 Total Publications

Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device.
Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: March 06, 2025
Similar Doctors
Expertise in
10
conditions
Dr. Thomas Coates
Hematology | Oncology
Expertise in
10
conditions
Dr. Thomas Coates
Hematology | Oncology

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (42.2 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances

Thomas Coates is a Hematologist and an Oncologist in Los Angeles, California. Dr. Coates is highly rated in 10 conditions, according to our data. His top areas of expertise are Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Stephen Forman
Expertise in
44
conditions
Dr. Stephen Forman
Hematology | Oncology
Expertise in
44
conditions
Dr. Stephen Forman
Hematology | Oncology

Stephen J. Forman, M.D.

1500 Duarte Rd, 
Duarte, CA 
 (34.1 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Forman is a Hematologist and an Oncologist in Duarte, California. Dr. Forman is highly rated in 44 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
15
conditions
Dr. Gottfried Konecny
Hematology | Oncology
Expertise in
15
conditions
Dr. Gottfried Konecny
Hematology | Oncology

Office

100 UCLA Medical Plz Ste 550, 
Los Angeles, CA 
 (47.1 miles away)
310-794-4955
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gottfried Konecny is a Hematologist and an Oncologist in Los Angeles, California. Dr. Konecny is highly rated in 15 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor.

Frequently Asked Questions about Dr. Chaitali Nangia

How do I make an appointment with Dr. Chaitali Nangia?

You can book an appointment with Dr. Chaitali Nangia by calling their office at 949-764-5347. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Chaitali Nangia a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Chaitali Nangia is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Chaitali Nangia specialize in?

While Dr. Chaitali Nangia is a Hematology, they have specific expertise in Breast Cancer, Olfactory Neuroblastoma, and Teratocarcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Chaitali Nangia participate in research or clinical trials?

Yes. Dr. Chaitali Nangia has published 18 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Chaitali Nangia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Chaitali Nangia accept my insurance?

Dr. Chaitali Nangia accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 949-764-5347 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nangia's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile